Apollo AyurVAID Launches India's First 'Tested Safe' Ayurveda Products
• Continues to build a full-stack Ayurveda enterprise with focus on comprehensive precision Ayurveda care and integrative medicine for patients across various clinical conditions
• Launches 50 SKUs across classical Ayurveda formulations, OTC products, and medical foods
• Targets nationwide reach and Rs. 500 crores in Products revenue in the next 5 years
Apollo AyurVAID, India's leading NABH-accredited, precision Ayurveda hospital network, announces its strategic foray into the Ayurveda product segment, marking a significant expansion beyond clinical care. The new portfolio spans classical formulations, OTC products, and medical foods, crafted to meet the growing demand for safe, clinically validated Ayurveda products in India's ~ Rs. 60,000 crore market growing at over 16% annually.
In an industry first, Apollo AyurVAID's product range features clinically proven formulations that are certified safe by NABL-accredited laboratories with respect to presence of heavy metals, aflatoxins, microbial content, etc., as applicable for different product types. Apollo AyurVAID's products set the highest, proof-backed, safety benchmark in the Ayurveda product market with the consumer able to verify test results (QR code on packaging) for each and every product they consume. This reinforces Apollo AyurVAID's resolve to offer safer, standardised, and effective Ayurveda products that the market can implicitly trust.
Dr. Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals and Chairperson, Apollo AyurVAID said, 'Apollo AyurVAID's foray into tested-safe Ayurveda products marks a pivotal step in redefining standards of safety, transparency, and efficacy in traditional medicine. This expansion builds on a strong foundation of clinical excellence and reflects a deep commitment to evidence-based, precision Ayurveda. By integrating innovation with time-honoured wisdom, Apollo AyurVAID is well on its way to shaping the future of integrative medicine in India and beyond.'
Commenting on this strategic initiative, Mr. Rajiv Vasudevan, Founder, MD, and CEO, Apollo AyurVAID said, 'With two decades of clinical excellence behind us, we are extending our understanding of precision Ayurveda and credibility into a high-potential consumer space. This new vertical not only complements our inpatient-outpatient care model but also opens scalable revenue opportunities and reinforces our vision of mainstreaming evidence-based Ayurveda services and products by making it accessible globally. We anticipate this portfolio will be a key growth driver, with a revenue aspiration of Rs. 500 crores in the next 5 years.'
The Ayurveda products division is being developed as a business unit of Apollo AyurVAID, while staying firmly rooted in Apollo AyurVAID's commitment to precision Ayurveda for personalised, safe, clinical-outcomes-driven health care.. While classical formulations will be available through prescription, the OTC and medical foods lines will be available through a wide network of retail and digital platforms. The OTC range features innovative medicine formats such as creams, transdermal pads, essential extracts, etc., for special customer segments (women, child, elder, etc.) and applications (pain, sleep, stress, skin etc.), with highest medical content assuring best-in-class product performance. Apollo AyurVAID has recently partnered with integrated systems biology platform company, Avesthagen Limited, to co-develop and offer scientifically validated, botanical-actives based dietary supplements that are sugar-free, artificial colour & flavours free; this shall be followed with an Ayurveda based medical foods range for specific clinical indications.
The classical and OTC product range are branded 'AyurVAID' while the dietary supplements are branded 'AvestaAyurVAID'. This strategic expansion reinforces Apollo AyurVAID's vision of building a credible, science-led ecosystem for precision Ayurveda and evolving into a full-spectrum Ayurveda company.
'As we enter the Ayurveda products space, our broader vision is to take the Apollo AyurVAID brand across the length and breadth of India. In the current fiscal we plan to expand our hospital network in an asset-light manner by adding 9 new points of presence, scaling our bed capacity to 350, aiming to treat over 50,000 patients. With a CAGR of 75% over the last 2–3 years, we are on track to surpass the annualised Rs. 100 crore revenue mark by mid next year - an unprecedented milestone in Ayurveda's services sector. This is just the beginning of our journey to take Apollo AyurVAID, India's most credible, precision Ayurveda care, to every corner of the country and across the globe,' added Mr. Rajiv Vasudevan.
Distribution for the new portfolio will follow a multi-tier strategy, with availability across Apollo AyurVAID's hospitals and clinics, the company's website, Apollo Pharmacies, Apollo 24|7 and leading e-commerce platforms. This integrated channel approach is designed to enable access and reach to a wider audience.
About Apollo AyurVAID
Apollo AyurVAID (www.ayurvaid.com) is India's leading chain of protocol-driven Ayurveda hospitals and integrative care centres, delivering evidence-based, 'Precision Ayurveda' for chronic disease reversal, management, and sustained wellbeing. Since its inception in 2005, Apollo AyurVAID has been committed to transforming Ayurveda into a mainstream, protocols, documentation and clinical-outcomes driven system of medicine with hospitals and clinics spread across Bengaluru, Chennai, New Delhi, Kochi, Almora and Hyderabad.
Founded in 2005 and part of the Apollo group since 2022, Apollo AyurVAID has emerged as a pivotal force in formalising Ayurveda-led integrative care, developing a unique care model that combines traditional Ayurvedic wisdom with modern clinical rigour. The chain of hospitals has demonstrated an impactful model of integrative care across specialties including neurology, oncology, nephrology, obstetrics and gynaecology, and metabolic disorders, with a focus on adjuvant therapy, palliative care, rehabilitation, and primary intervention. Apollo AyurVAID's unique 'Whole Person Care' approach considers the whole person to treat multimorbidity, not just at symptom level but at root-cause level, and supports health across the entire life cycle, from prevention and treatment to rehabilitation, survivorship and wellbeing.
The first and only Ayurveda institution to receive the prestigious QCI DL Shah National Quality Award (2012), Apollo AyurVAID is also India's first NABH-accredited Ayurveda hospital (2010). It is also the first to gain NABH accreditation for Ayurveda para surgery (2013) and five hospitals in its countrywide network are NABH-accredited. In 2023, it became the first and only QAI-accredited Ayurveda and integrative medicine based Transition Care Centre in India.
(Disclaimer: The above press release comes to you under an arrangement with Newsvoir and PTI takes no editorial responsibility for the same.). PTI
This is an auto-published feed from PTI with no editorial input from The Wire.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
India pharma, healthcare revenue to grow steadily in Q1FY26E; EBITDA margins under pressure: Report
Indian pharma and healthcare sector will witness steady revenue growth in the first quarter of the Financial Year 2026 (Q1FY26E), but concerns loom as EBITDA margins are expected to decline amid rising input costs and pricing pressures, according to a report by HDFC Securities. The report added that the pharma sector firms studied by it may witness a 11 per cent year-on-year (YoY) sales growth, driven by an 11 per cent YoY increase in the India business along with 2 per cent QoQ growth in US sales (+2 per cent YoY). The EBITDA, which stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, is a financial metric used to assess a company's profitability and operational efficiency. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 이 게임은 대부분의 TV 프로그램보다 더 재미있어요 – 게다가 무료예요. Raid: Shadow Legends 플레이하기 Undo The report stated that EBITDA margins for the pharma segment are expected to decrease by 42bps YoY, driven by price erosion in the US and an expected increase in research and development (R&D). The hospital business is projected to grow by 15 per cent YoY, as muted occupancy will be partly supported by steady ARPOB, or Average Revenue Per Occupied Bed, which is a key performance indicator used in the healthcare industry to assess a hospital's financial performance. Live Events India's pharmaceutical market for FY 2023-24 is valued at USD 50 billion, with domestic consumption valued at USD 23.5 billion and exports valued at USD 26.5 billion. The domestic pharma industry is considered to be the world's third-largest by volume and 14th in terms of value of production. With an extremely diversified product base covering generic drugs, bulk drugs, over-the-counter drugs, vaccines, biosimilars, and biologics, the Indian pharmaceutical industry has a strong presence at the global level. According to National Accounts Statistics 2024, published by the Ministry of Statistics and Programme Implementation, total output for industry, i.e., Pharmaceuticals, medicinal and botanical products, is Rs. 4,56,246 crores for FY 2022-23 at constant prices, of which value added is Rs 1,75,583 crores.


Hans India
an hour ago
- Hans India
Why You Should Skip Curd and Embrace These 6 Gut-Friendly Foods
Curd is a beloved staple in Indian households—creamy, cooling, and often the star of many regional delicacies. But when the monsoon clouds roll in, ancient Ayurvedic wisdom advises hitting pause on this dairy favourite. While it may sound surprising, there's solid reasoning behind this age-old recommendation. The monsoon season brings a shift in temperature and humidity, creating an environment that can disrupt digestion and immunity. Ayurveda, India's holistic healing system, suggests that consuming curd during this time might do more harm than good. But why exactly? Why Curd Might Not Be the Best Choice During Monsoon 1. Ayurveda's Take: Dosha Imbalance According to Ayurvedic principles, the rainy season tends to disturb the Vata and Pitta doshas. Curd, with its heavy and sour nature, can aggravate this imbalance—making the body more susceptible to seasonal illnesses like colds, allergies, and stomach disorders. 2. Weakening of Digestive Fire (Agni) Curd's natural cooling properties are known to suppress Agni, or digestive fire. This suppression can lead to issues like gas, bloating, and indigestion—especially when consumed plain. Ayurvedic experts often recommend tempering curd with warming spices like roasted cumin or black pepper to offset these effects. 3. Respiratory Issues Amplified Another concern is curd's mucus-producing quality. In a season where humidity already elevates moisture levels in the air, curd can further thicken mucus in the respiratory tract, increasing the risk of congestion, colds, and coughs. Gut-Friendly Foods to Boost Health This Monsoon If you're looking to give your digestive system a seasonal reset, here are six power-packed alternatives to curd that promote better gut health: 1. Ginger: Nature's Digestive Tonic With anti-inflammatory and warming properties, ginger helps keep the digestive system calm and efficient. It's a perfect monsoon companion to fight nausea and bloating. 2. Garlic: The Natural Antimicrobial Agent Raw garlic contains allicin, a compound known for its antimicrobial and antifungal effects. It acts as a protective shield for your gut against harmful pathogens. 3. Banana: Prebiotic and Potassium-Rich Easy to digest and packed with potassium, bananas help maintain fluid balance and feed the gut's beneficial bacteria, supporting a healthy microbiome. 4. Turmeric: The Golden Gut Protector Curcumin, turmeric's active compound, is celebrated for its anti-inflammatory and antioxidant effects. It helps strengthen the gut lining and prevents inflammation. 5. Oats: Fibre-Rich and Satiating High in soluble fibre, oats promote regular bowel movements and feed beneficial gut bacteria, making them a great breakfast option during monsoons. 6. Leafy Greens: Nutrient-Dense and Detoxifying Leafy vegetables like spinach, kale, and methi are rich in fibre, vitamins, and antioxidants. They help regulate digestion and encourage the growth of healthy gut flora. While curd may be a staple in your diet, it's wise to be cautious with its consumption during monsoon. Instead, nourish your body with foods that fortify the gut and enhance overall immunity. A small seasonal adjustment can go a long way in keeping you healthy and energetic through the rains.


Business Standard
2 hours ago
- Business Standard
Indegene launches NEXT Medical Writing Automation
Indegene has announced the launch of NEXT Medical Writing Automation to accelerate the creation of high-quality documents across clinical development, regulatory submissions, and beyond. NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI). Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. NEXT Medical Writing Automation combines Indegenes decades of domain knowledge with the power of its AI engine, Cortex. Sameer Lal, SVP, Enterprise Medical Solutions, Indegene, said, With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. We see this platform as more than automationits about elevating the entire practice of medical writing. Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting. Indegene is a digital-first life sciences commercialization company that partners with biopharmaceutical, emerging biotech, and medical device companies to develop products, bring them to market, and enhance their impact throughout the product lifecyclemore effectively, efficiently, and in a modern, technology-driven manner. The companys consolidated net profit jumped 24.1% to Rs 117.60 crore on 12.3% increase in net sales to Rs 755.60 crore in Q4 FY25 over Q4 FY24. The scrip declined 1.02% to settle at Rs 564.35 on the BSE.